trialsTrialRecruiting

Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients

A phase 1/2 trial of TC011 in diffuse large b-cell lymphoma and follicular lymphoma, run by TICAROS Co., Ltd., now recruiting.

Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients is a phase 1/2 interventional study registered as NCT07473167 by TICAROS Co., Ltd., with 98 participants planned, started 2023-08-03 and due to reach its primary completion in 2028-02-11. Interventions recorded: TC011. Conditions listed: Relapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), High-grade B-cell Lymphoma (HGBL). No results are recorded here; the registry entry is the source.

Setting

A Multi-center, Single Arm, Open-label Phase 1/2 Clinical Trial to Evaluate Safety, and to Explore Efficacy of TC011(CD19 Targeted CAR-T) in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients

Phase

Phase 1/2

Sponsor

TICAROS Co., Ltd.

Registry

NCT07473167

Started

2023-08-03

Enrolled

98 enrolled

Connected

3top

cancers

Diffuse large B-cell lymphoma Follicular lymphoma

drugs

Phase 2CAR-T cell therapy

TC011

Evidence strength18/100 · Preliminary

How much and what kind of evidence, not how big the benefit. Click for the breakdown.

Phase 1/2+8
98 enrolled+10
No structured primary endpoint0
Result: recruiting0
No independent replication recorded0

Formula disclosed on the evidence page.

ProvenanceLast edited 2026-09-16 · Jude Gomila · Header signup, trial wave 5 and Ask weighting · diff · file

Sources & links

ClinicalTrials.gov NCT07473167

Data

JSON ·

Follow this page

Follow by feed

Wrong or missing?

Propose a change with a source. Organisations can update their own records. Every suggestion is reviewed, safety-checked and validated before it goes live; nothing is edited directly.

Suggest an editDiscuss start a thread

Cancers

Products

TC011

Not yet reviewedNeeds expert (clinical) review. Review this page or see the review queue and roster.

Model panel commentary is coming to this page: machine commentary, not clinical review.

trialsTrialRecruiting

Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients

A phase 1/2 trial of TC011 in diffuse large b-cell lymphoma and follicular lymphoma, run by TICAROS Co., Ltd., now recruiting.

Setting

Phase

Phase 1/2

Sponsor

TICAROS Co., Ltd.

Registry

NCT07473167

Started

2023-08-03

Enrolled

98 enrolled

Connected

3top

cancers

Diffuse large B-cell lymphoma Follicular lymphoma

drugs

Phase 2CAR-T cell therapy

TC011

Evidence strength18/100 · Preliminary

How much and what kind of evidence, not how big the benefit. Click for the breakdown.

Phase 1/2+8
98 enrolled+10
No structured primary endpoint0
Result: recruiting0
No independent replication recorded0

Formula disclosed on the evidence page.

ProvenanceLast edited 2026-09-16 · Jude Gomila · Header signup, trial wave 5 and Ask weighting · diff · file

Sources & links

ClinicalTrials.gov NCT07473167

Data

JSON ·

Follow this page

Follow by feed

Wrong or missing?

Propose a change with a source. Organisations can update their own records. Every suggestion is reviewed, safety-checked and validated before it goes live; nothing is edited directly.

Suggest an editDiscuss start a thread

Cancers

Products

TC011

Not yet reviewedNeeds expert (clinical) review. Review this page or see the review queue and roster.

Model panel commentary is coming to this page: machine commentary, not clinical review.

Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients

Overview

Connected

cancers

drugs

Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients

Overview

Connected

cancers

drugs